These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7768258)

  • 1. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.
    Chu KM; Shieh SM; Hu OY
    Eur J Clin Pharmacol; 1995; 47(6):537-42. PubMed ID: 7768258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
    Chu KM; Hu OY; Shieh SM
    Drug Metab Dispos; 1999 Jun; 27(6):701-9. PubMed ID: 10348800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
    Bell ET; Devi JL; Chiu S; Zahra P; Whittem T
    J Vet Pharmacol Ther; 2016 Feb; 39(1):54-61. PubMed ID: 25989021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral pimobendan in healthy cats.
    Hanzlicek AS; Gehring R; Kukanich B; Kukanich KS; Borgarelli M; Smee N; Olson EE; Margiocco M
    J Vet Cardiol; 2012 Dec; 14(4):489-96. PubMed ID: 23116650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs.
    Yata M; McLachlan AJ; Foster DJ; Page SW; Beijerink NJ
    J Vet Pharmacol Ther; 2016 Feb; 39(1):45-53. PubMed ID: 25997373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
    Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
    J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency.
    Przechera M; Roth W; Kühlkamp V; Risler T; Haehl M
    Eur J Clin Pharmacol; 1991; 40(1):107-11. PubMed ID: 2060537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of the enantiomers of pimobendan and its main metabolite in rat plasma by high-performance liquid chromatography.
    Asakura M; Nagakura A; Tarui S; Matsumura R
    J Chromatogr; 1993 Apr; 614(1):135-41. PubMed ID: 8496273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
    Kuriya Si; Ohmori S; Hino M; Ishii I; Nakamura H; Senda C; Igarashi T; Kiuchi M; Kitada M
    Drug Metab Dispos; 2000 Jan; 28(1):73-8. PubMed ID: 10611143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison.
    Pahernik SA; Schmid J; Sauter T; Schildberg FW; Koebe HG
    Xenobiotica; 1995 Aug; 25(8):811-23. PubMed ID: 8779223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
    Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability of bemoradan, a long-acting inodilator in healthy males.
    Huang SM; Brusser L; Chien SC; Simon D; Smith IL; Abrams LS; Lasseter K
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):62-4. PubMed ID: 8004360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
    Hagemeijer F; Roth W; Brand HJ
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
    Guzman DS; Beaufrère H; KuKanich B; Barker SA; Brandão J; Paul-Murphy J; Tully TN
    J Avian Med Surg; 2014 Jun; 28(2):95-101. PubMed ID: 25115037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs.
    Schneider P; Güttner J; Eckenfels A; Heinzel G; von Nicolai H; Trieb G; Lehmann H
    Exp Toxicol Pathol; 1997 Aug; 49(3-4):217-24. PubMed ID: 9314056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.